Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.
Psychedelics
Will MindMed NASDAQ Listing Be The Next Sector-Wide Catalyst?
The Compass Pathways IPO was a huge catalyst for the whole sector. Will a MindMed up-listing have the same impact?
How Medtech Is Taking Healthcare Into The 21st Century
What is medtech? It's the wave of the future for healthcare.
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
Mydecine begins the dual listing process to obtain an LSE listing.
Mind Cure Health : Announces Geoff Belair as Chief Technology Officer
Mind Cure brings in an expert in fintech to be its new CTO.
The 8 Best Reasons To Invest In Psychedelic Stocks
Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.
Primo Nutraceuticals Inc., Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of Psilocybin Mushrooms
Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.
Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council
Numinus rolls out the list of Advisors on its psychedelics Advisory Council
Heroic Hearts Project and Field Trip Health Ltd. enter into a strategic relationship to increase legal psychedelic therapy access for military veterans in North America
Field Trip's new strategic partnership will facilitate bringing its ketamine-assisted psychotherapy for PTSD to military veterans.
Numinus (CSE:NUMI) or Mydecine (CSE:MYCO)? Two Psychedelics Investing Options
Both Numinus and Mydecine have been rising recently on big volume. Which is the better bet?
Pharmather (CSE:PHRM) Is The Latest Psychedelics IPO
The newest psychedelics company plans to focus on both ketamine- and psilocybin-assisted psychedelics R&D.
Mind Cure Announces Addition of Neuroscientist Dr. Wolfram Tetzlaff to Scientific Advisory Board
Mind Cure adds an expert in neuroscience and nutrition to its Advisory Board.
Psychedelic Stock Rally Spreads, Big Gains Beyond CMPS
Industry heavyweight Compass Pathways launched the current rally in psychedelic stocks. But four other stocks have been outperforming CMPS.
MindMed Announces $25 Million Bought Deal Public Offering
MindMed announces a CAD$25 million bought-deal financing at CAD$1.05 per unit.
MindMed Cashes In, $25 Million Bought Deal Financing
MindMed has capitalized on its recent market success to raise new capital on more favorable terms.